Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!
Learn MoreMetastasis is the process by which cancer cells migrate through lymph or blood vessels, leading to the formation of new tumors in distant organs. It is the primary cause of death in the majority of bladder cancer cases. At Alfa Cytology, we specialize in providing our clients with tumor metastatic models specifically designed for bladder cancer research.
In muscle-invasive bladder cancer, approximately 25 percent will either have metastases at the time of diagnosis or develop metastases later on. The most common sites of metastasis in bladder cancer include the lymph nodes, lungs, liver, and bones. Local infiltration and peripheral lymph node metastasis are more frequently observed in bladder cancer metastasis, while distant metastasis occurs less frequently.
Although metastasis is the cause of most bladder cancer-related deaths, the mechanisms of metastatic disease are not yet fully understood, in part due to the lack of preclinical in vivo models. The development of advanced preclinical models of metastasis will help us understand bladder cancer progression and develop new therapies for metastatic bladder cancer.
Alfa Cytology, a leading provider of preclinical contract research organization (CRO) services, specializes in tumor metastatic model development for bladder cancer. Our services include but are not limited to:
Development of Orthotopic Mouse Models | Development of Patient-Derived Xenografts (PDX) | Development of Genetically Engineered Mouse Models (GEMMs) |
|
|
|
By implanting bladder cancer cells directly into the bladder wall of mice, we recreate the complex interactions between tumor cells and the bladder microenvironment. | Our PDX service involves the transplantation of patient-derived tumor tissue or cells into immunocompromised mice. This enables the preservation of the genetic and phenotypic characteristics of the original patient tumor. | We specialize in the development of GEMMs for bladder cancer research, where specific mutations or alterations associated with bladder cancer are introduced into mice. |
Models | Functions |
---|---|
Orthotopic Mouse Models |
|
PDX |
|
Genetically Engineered Mouse Models (GEMMs) |
|
At Alfa Cytology, we are committed to providing comprehensive preclinical CRO services in the field of bladder cancer research. Our tumor metastatic model development service offers advanced orthotopic mouse models, PDX, and genetically engineered mouse models tailored to the study of bladder cancer metastasis. Our team of experts is dedicated to accelerating your research projects, enabling early diagnosis, and developing effective therapeutics strategies for bladder cancer. If you have any needs, please contact us.
Reference
Alfa Cytology is dedicated to drug development and preclinical services for bladder cancer.